Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;90(7):843-844.
doi: 10.1136/jnnp-2018-319364. Epub 2018 Nov 8.

Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease

Roberto Angel Ortega  1   2 , Mark Groves  3   2 , Anat Mirelman  4   5   6   7 , Roy N Alcalay  8 , Deborah Raymond  3   2 , Sonya Elango  3   2 , Helen Mejia-Santana  8 , Nir Giladi  4   6   7 , Karen Marder  8   9 , Susan B Bressman  3   2 , Rachel Saunders-Pullman  3   2
Affiliations

Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease

Roberto Angel Ortega et al. J Neurol Neurosurg Psychiatry. 2019 Jul.
No abstract available

Keywords: Parkinson's disease; genetics; movement disorders; neurogenetics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SBB and RS-P have received consulting fees from Denali Therapeutics Inc. RNA has received consulting fees from Denali, Biogen and Genzyme/Sanofi. NG serves as a member of the Editorial Board for the Journal of Parkinson's Disease. He serves as consultant to Sionara, Accelmed, Teva, NeuroDerm, IntecPharma, Pharma2B, Denali and Abbvie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, Sanofi-Genzyme, Bial and Movement Disorder Society. NG received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program and the Israel Science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer.

References

    1. Shanker V, Groves M, Heiman G, et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson’s disease. Mov Disord 2011;26:1875–80. - PMC - PubMed
    1. Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-asssociated parkinson disease population. JAMA Neurol 2018;75:312–9. - PMC - PubMed
    1. Alcalay RN, Mirelman A, Saunders-Pullman R. Parkinson disease phenotype in ashkenazi jews with and without LRRK2 G2019S mutations. movement disorders : official journal of the movement disorder society. Mov Disord 2013;28:1966–71. - PMC - PubMed
    1. Puschmann A, Englund E, Ross OA, et al. First neuropathological description of a patient with Parkinson’s disease and LrrK2 p.N1437H mutation. Parkinsonism Relat Disord 2012;18:332–8. - PMC - PubMed
    1. Mann JJ, Arango VA, Avenevoli S, et al. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 2009;65:556–63. - PMC - PubMed

Publication types

Substances